Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY® (mobocertinib) in the U.S. for adult patients with epidermal growth fa...
Takeda TSE4502NYSETAK today announced that following discussions with the U.S. Food and Drug Administration FDA it will be working with the FDA towards a voluntary withdrawal of EXKIVITY mobocertinib in the U.S. for adult patients with epidermal growth factor receptor EGFR Exon20 ion mutationpositive ion locally advanced or metastatic nonsmall cell lung cancer NSCLC whose disease has progressed on or after platinumbased chemotherapy.
Takeda ; class='js-l-obf link link--blue'
Epilepsy is a condition that impacts about 3.4 million people in the U.S.1 John is one of many people living with uncontrolled epilepsy who also experiences seizure clusters [3], which are marked by periods of increased seizure activity – which can be defined as two or more seizures in a 24-hour period. [2]
Data Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual...